Skip to main content
Editorial17 November 2022
Editorial: Molecular chaperones and human disease

in understanding the roles of molecular chaperones in the progression of model diseases with the prospects of targeting molecular chaperones toward the identification of novel drug therapies.Heat shock proteins (Hsps) are some of the most studied molecular chaperones that are associated with several chaperonopathies. They particularly play an important role in the pathogenesis of malaria, which is caused by the parasite Plasmodium falciparum. P. falciparum exhibits a very complex life cycle where its development partly occurs in a poikilothermic mosquito and a homeothermic human host. Hsps, therefore, play an integral role in ensuring that proteostasis is maintained throughout the parasite's life cycle and may thus be exciting antimalarial drug targets. Despite several efforts in the development of novel antimalarial therapies, drug resistance to front-line malarial treatments presents an urgent need for the development of novel therapies that are more reliable as highlighted by (Mrozek et al., 2022). Using in vitro and cell-based assays, Muthelo and colleagues reported that the anti-cancer drug 2-Phenylthynesulfonamide (PES) exhibits antiplasmodial activity and capability to inhibit the functions of the P. falciparum cytosol-localized chaperones PfHsp70-1 and PfHop (Muthelo et al., 2022). Barth and colleagues reviewed the current state of knowledge about the Hsp70 family of chaperones focusing on the suitability of these proteins and interactions for drug development (Barth et al., 2022). Together with the Hsp90s, Hsp70 proteins have been widely studied in several disease models though, to date, there haven't been many FDA-approved Hsp70 drugs. A review by Michael Daniyan and colleagues (Daniyan et al., 2022) looked into the roles of the exported parasite chaperone PfHsp70-x in the pathophysiology of cerebral malaria. The article also explored the possible links between host-parasite chaperones, and neurotransmitters, in relation to other molecular signalling components in the development of cerebral malaria (Daniyan et al., 2022). This signalling pathway may provide further insights in antimalarial drug discovery. Collectively, the findings from these studies may contribute to the ongoing efforts in identifying novel antimalarial therapies, especially in the wake of growing parasite resistance against currently used drugs.Chaperone/co-chaperone inhibition is being explored as a potential therapeutic target for several diseases.A review by Caillet et al., 2022(Caillet et al., 2022 looks into the potential roles of molecular chaperones in mediating cell and systemic stress in COVID-19. The article discusses the roles of the host stress response as a convergent point for COVID-19 and several non-communicable diseases while further assessing the merits of targeting the host stress response to manage the clinical outcomes of COVID-19. It sets an interesting argument on the possible roles Hsps might play in COVID-19 and the potential of targeting Hsps in novel COVID-19 therapy. Using an in silico approach, Jamabo et al., 2022 (Jamabo et al., 2022) conducted a structural analysis of the Trypanosoma brucei (T. brucei) Hsp90 variants in relation to human and other trypanosomal species. T. brucei is responsible for African trypanosomiasis which is a neglected tropical disease mostly endemic to sub-Saharan Africa. The parasite is spread by insects (tsetse fly). Similar to P. falciparum, the trypanosome relies on heat shock proteins for survival in the insect vector and mammalian host. In their analysis, Jambo et al., 2022 identified a total of eighteen putative T. brucei Hsp90 co-chaperones with one notable absence being cell division cycle 37 (Cdc37) (Jamabo et al., 2022). Their findings provide an updated framework for approaching Hsp90 and its interactions as drug targets in the African trypanosome (Jambo et al., 2022).Hsp90 has previously attracted a lot of attention in drug discovery research and several Hsp90-targeting drugs have gone through various stages of clinical trials in the development of treatments for cancers and cardiovascular diseases. A study by Scalia and colleagues (2022) (Scalia et al., 2022) reported the reduced Hsp90 expression levels observed in a mutant version of the CCT5 subunit from a patient with distal motor neuropathy. This indicates that the imbalance of the chaperone has a negative impact which potentially triggers the development of distal motor neuropathy. Follow-up studies could provide further information on how Hsp-dysregulation triggers neurophysiological disorders. The role of Hsp90 in tumor progression and prognosis was also investigated in the development of small cell lung cancer (Huang et al., 2022). Upon analyzing the relationship between eHSP90α expression and clinicopathological features, eHSP90α and NSE were found to be positively correlated in patients with small cell lung cancer (Huang et al., 2022). This study provided new evidence for the efficacy response and prognostic assessment of SCLC with eHSP90α being suggested to be a potential SCLC biomarker.Altogether, the articles included in this topic highlight the new advances that have been made in the application of molecular chaperones in translational medicine. The section also reported on the successes and potential use of Hsps in novel drug therapies and biomarkers for several disease models. As there has been rapid development in the field of chaperone biology, we envision that novel, groundbreaking findings will further contribute to the development of applicable solutions in drug and biomarker discovery.

2,768 views

ORIGINAL RESEARCH
7 October 2022
A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues
Alexander Mrozek, 6 more and Hee-Won Park

4,173 views

7 citations

5,019 views

10 citations

Plasmodium falciparum Hsp70-1 (PfHsp70-1; PF3D7_0818900) and PfHsp90 (PF3D7_0708400) are essential cytosol localized chaperones of the malaria parasite. The two chaperones form a functional complex via the adaptor protein, Hsp90-Hsp70 organising protein (PfHop [PF3D7_1434300]), which modulates the interaction of PfHsp70-1 and PfHsp90 through its tetracopeptide repeat (TPR) domains in a nucleotide-dependent fashion. On the other hand, PfHsp70-1 and PfHsp90 possess C-terminal EEVD and MEEVD motifs, respectively, which are crucial for their interaction with PfHop. By coordinating the cooperation of these two chaperones, PfHop plays an important role in the survival of the malaria parasite. 2-Phenylthynesulfonamide (PES) is a known anti-cancer agent whose mode of action is to inhibit Hsp70 function. In the current study, we explored the antiplasmodial activity of PES and investigated its capability to target the functions of PfHsp70-1 and its co-chaperone, PfHop. PES exhibited modest antiplasmodial activity (IC50 of 38.7 ± 0.7 µM). Furthermore, using surface plasmon resonance (SPR) analysis, we demonstrated that PES was capable of binding recombinant forms of both PfHsp70-1 and PfHop. Using limited proteolysis and intrinsic fluorescence-based analysis, we showed that PES induces conformational changes in PfHsp70-1 and PfHop. In addition, we demonstrated that PES inhibits the chaperone function of PfHsp70-1. Consequently, PES abrogated the association of the two proteins in vitro. Our study findings contribute to the growing efforts to expand the arsenal of potential antimalarial compounds in the wake of growing parasite resistance against currently used drugs.

4,099 views

17 citations

Neurotransmitters and molecular chaperones interactions in cerebral malaria: Is there a missing link?
REVIEW
24 August 2022
Neurotransmitters and molecular chaperones interactions in cerebral malaria: Is there a missing link?
Michael Oluwatoyin Daniyan, 1 more and Olufunso Bayo Adeoye
Plasmodium falciparum is responsible for the most severe and deadliest human malaria infection. The most serious complication of this infection is cerebral malaria. Among the proposed hypotheses that seek to explain the manifestation of the neurological syndrome in cerebral malaria is the vascular occlusion/sequestration/mechanic hypothesis, the cytokine storm or inflammatory theory, or a combination of both. Unfortunately, despite the increasing volume of scientific information on cerebral malaria, our understanding of its pathophysiologic mechanism(s) is still very limited. In a bid to maintain its survival and development, P. falciparum exports a large number of proteins into the cytosol of the infected host red blood cell. Prominent among these are the P. falciparum erythrocytes membrane protein 1 (PfEMP1), P. falciparum histidine-rich protein II (PfHRP2), and P. falciparum heat shock proteins 70-x (PfHsp70-x). Functional activities and interaction of these proteins with one another and with recruited host resident proteins are critical factors in the pathology of malaria in general and cerebral malaria in particular. Furthermore, several neurological impairments, including cognitive, behavioural, and motor dysfunctions, are known to be associated with cerebral malaria. Also, the available evidence has implicated glutamate and glutamatergic pathways, coupled with a resultant alteration in serotonin, dopamine, norepinephrine, and histamine production. While seeking to improve our understanding of the pathophysiology of cerebral malaria, this article seeks to explore the possible links between host/parasite chaperones, and neurotransmitters, in relation to other molecular players in the pathology of cerebral malaria, to explore such links in antimalarial drug discovery.

5,373 views

10 citations

Host cell stress response as a predictor of COVID-19 infectivity and disease progression
The coronavirus disease (COVID-19) caused by a coronavirus identified in December 2019 has caused a global pandemic. COVID-19 was declared a pandemic in March 2020 and has led to more than 6.3 million deaths. The pandemic has disrupted world travel, economies, and lifestyles worldwide. Although vaccination has been an effective tool to reduce the severity and spread of the disease there is a need for more concerted approaches to fighting the disease. COVID-19 is characterised as a severe acute respiratory syndrome (SARS). The severity of the disease is associated with a battery of comorbidities such as cardiovascular diseases, cancer, chronic lung disease, and renal disease. These underlying diseases are associated with general cellular stress. Thus, COVID-19 exacerbates outcomes of the underlying conditions. Consequently, coronavirus infection and the various underlying conditions converge to present a combined strain on the cellular response. While the host response to the stress is primarily intended to be of benefit, the outcomes are occasionally unpredictable because the cellular stress response is a function of complex factors. This review discusses the role of the host stress response as a convergent point for COVID-19 and several non-communicable diseases. We further discuss the merits of targeting the host stress response to manage the clinical outcomes of COVID-19.

4,898 views

13 citations

HSP70 and their co-chaperones in the human malaria parasite P. falciparum and their potential as drug targets
MINI REVIEW
5 August 2022
HSP70 and their co-chaperones in the human malaria parasite P. falciparum and their potential as drug targets
Julian Barth, 1 more and Jude M. Przyborski
As part of their life-cycle, malaria parasites undergo rapid cell multiplication and division, with one parasite giving rise to over 20 new parasites within the course of 48 hours. To support this, the parasite has an extremely high metabolic rate and level of protein biosynthesis. Underpinning these activities, the parasite encodes a number of chaperone/heat shock proteins, belonging to various families. Research over the past decade has revealed that these proteins are involved in a number of essential processes within the parasite, or within the infected host cell. Due to this, these proteins are now being viewed as potential targets for drug development, and we have begun to characterize their properties in more detail. In this article we summarize the current state of knowledge about one particular chaperone family, that of the HSP70, and highlight their importance, function, and potential co-chaperone interactions. This is then discussed with regard to the suitability of these proteins and interactions for drug development.

5,416 views

18 citations

ORIGINAL RESEARCH
11 July 2022
High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer
Baoyue Huang, 7 more and Litu Zhang

2,825 views

13 citations

ORIGINAL RESEARCH
2 June 2022
Muscle Histopathological Abnormalities in a Patient With a CCT5 Mutation Predicted to Affect the Apical Domain of the Chaperonin Subunit
Federica Scalia, 17 more and Francesco Cappello

3,848 views

9 citations